DexCom (DXCM, Financial), a leader in diabetes management systems, has received an updated evaluation from Citigroup analyst Joanne Wuensch. On May 22, 2025, Wuensch maintained a 'Buy' rating for the company while raising the stock's price target from USD 82.00 to USD 102.00. This adjustment represents a significant 24.39% increase in the price target.
The decision by Citigroup to maintain its 'Buy' rating on DexCom (DXCM, Financial) underscores the confidence in the company's ongoing performance and potential for continued growth. The new price target reflects positive sentiment and suggests an optimistic outlook for DexCom's market position and future profitability.
Investors will be monitoring DexCom (DXCM, Financial) as the company continues to develop and market its innovative technology in the healthcare sector. The updated price target of USD 102.00 is indicative of the analyst's belief in the company's strategic initiatives and expansion capabilities.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for DexCom Inc (DXCM, Financial) is $98.51 with a high estimate of $115.00 and a low estimate of $82.00. The average target implies an upside of 16.19% from the current price of $84.79. More detailed estimate data can be found on the DexCom Inc (DXCM) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, DexCom Inc's (DXCM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM, Financial) in one year is $164.82, suggesting a upside of 94.4% from the current price of $84.785. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the DexCom Inc (DXCM) Summary page.
